How IGC Pharma Is Using AI to Transform Alzheimer’s Research

Jul 22, 2026

👉 Watch the full interview here:

IGC Pharma CEO Ram Mukunda discusses how the company is applying artificial intelligence to Alzheimer’s research, including AI-powered patient risk assessment and data harmonization technologies designed to support researchers and healthcare professionals.

Watch the full interview to learn more about IGC Pharma’s AI initiatives, clinical development strategy, and vision for advancing healthcare innovation.

#IGCPharma #ArtificialIntelligence #AI #Biotechnology #HealthcareInnovation #Alzheimers #HealthTech #MedTech #BusinessNews #Investing #BiotechStocks #MachineLearning #Innovation #Technology #NASDAQ

How IGC Pharma Is Using AI to Transform Alzheimer’s Research

Recommended

Stewards CEO Bilal Adam: Global Investment Strategy, Private Credit and Nasdaq Growth

BioVie CEO: Promising Phase 2 Results for Long COVID and Parkinson’s Disease

FreeCast CEO: How Its Streaming Software Platform Could Generate Multiple Revenue Streams

American Fusion Expands Texas Data Center Pipeline and Advances Texatron Testing Plans

BioVie Reports Positive Phase 2 Parkinson’s Trial Results for Bezisterim in Key Patient Subgroup

BioVie Reports Significant Long COVID Symptom Improvements in Phase 2 Clinical Trial

How IGC Pharma Is Using AI to Transform Alzheimer’s Research

Recommended

Stewards CEO Bilal Adam: Global Investment Strategy, Private Credit and Nasdaq Growth

BioVie CEO: Promising Phase 2 Results for Long COVID and Parkinson’s Disease

FreeCast CEO: How Its Streaming Software Platform Could Generate Multiple Revenue Streams

American Fusion Expands Texas Data Center Pipeline and Advances Texatron Testing Plans

BioVie Reports Positive Phase 2 Parkinson’s Trial Results for Bezisterim in Key Patient Subgroup

BioVie Reports Significant Long COVID Symptom Improvements in Phase 2 Clinical Trial

Share

Investor Accreditation

For Individuals

Thank You!